Hair loss is a chronic disorder that affects many people; however, a complete treatment has not yet been developed. Therefore, new therapeutic agents for preventing hair loss must be developed, and electromagnetic field (EMF) therapy has been proven to be a promising medical treatment in various fields, including hair loss treatment. This study evaluated the effect of extremely low-frequency electromagnetic field (ELF-EMF) intensity and exposure time by analyzing the expression of cytokines and anagen-related molecules, which influence hair activation and growth, in hair bulb spheroid (HBS) and hair follicle (HF) organ cultures. ELF-EMFs did not induce toxicity in the HBSs, as verified via the lactate dehydrogenase (LDH) assay. Moreover, an ELF-EMF intensity of 5-20 G promoted the expression of ALP, versican, β-catenin, and several cytokines (VEGF, PDGF, FGF-10, and ET-1) in HBSs. Immunohistochemical staining showed that ELF-EMF at an intensity of 5-20 G upregulated ALP and β-catenin and decreased TUNEL staining in HBS. Moreover, HFs exposed to ELF-EMF for 60 min exhibited an increase in hair length and a 1.5-fold increase in IL-4, ICAM-1, ALP, and versican mRNA expression compared to the control. Immunohistochemical staining indicated that 60 min of ELF-EMF can increase the expression of ALP and β-catenin and decreases TUNEL staining in organ cultures. Collectively, our results demonstrated that ELF-EMF exposure at a 10 G intensity for 60 min promoted hair shaft growth in HFs due to the effect of cytokines and adhesion molecules via the Wnt/β-catenin pathway. Therefore, ELF-EMF is a promising treatment for hair loss.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024517 | PMC |
http://dx.doi.org/10.3390/biomedicines10040924 | DOI Listing |
Cutis
December 2024
Drs. Lu, Du, Zhao, and Fan and Lingbo Bi, Chaofan Wang, and Yunbu Ding are from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China. Yige Fan is from the Mayo Clinic, Rochester, Minnesota.
In this retrospective study, we analyzed the prevalence and impact of pediatric androgenetic alopecia (AGA). Over a 14-year period, 133 pediatric patients were evaluated, with manifestations of AGA appearing as early as age 10 years. The analysis included factors such as body mass index (BMI), family history of AGA, comorbidities, laboratory results, and patterns of hair loss.
View Article and Find Full Text PDFDermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
J Cutan Med Surg
January 2025
Department of Dermatology, Venereology and Leprology, Sundaram Hospital, Trichy, Tamil Nadu, India.
Background: Intralesional (IL) steroids are the first-line treatment option for localized alopecia areata (AA). The present study aimed to compare the efficacy of topical calcipotriol with IL triamcinolone acetonide versus IL triamcinolone acetonide alone in AA.
Methods: This randomized single-blinded clinical trial was conducted in a dermatology outpatient department.
Cureus
December 2024
Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, PAK.
Background: Breast cancer is one of the most common cancers among Pakistani women. It is mostly diagnosed at stage 2, requiring chemotherapy in certain cases. Chemotherapy is of two types: adjuvant and neoadjuvant.
View Article and Find Full Text PDFNat Prod Res
January 2025
Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, India.
Linn., commonly known as the 'Tree of Sadness' belongs to Oleaceae family. In Ayurvedic, Siddha, Unani, and Homeopathic therapeutic systems, it has been used to treat various conditions, including ulcers, skin diseases, hair loss, piles, liver diseases, rheumatism, and malarial fevers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!